What Valink Therapeutics does

Valink Therapeutics is a preclinical biopharmaceutical company developing bispecific antibody-drug conjugates (bsADCs) and complementary multimodal ADC technologies for solid tumor indications including colorectal cancer and non-small cell lung cancer. Founded in 2021 as LiliumX and rebranded in November 2023, the company is a spinout from the University of Oxford's Department of Biochemistry and holds licenses to foundational protein conjugation IP including the SpyTag/SpyCatcher system.

The company's core asset is the LiliumX discovery platform, a proprietary engine built on three pillars: synthetic protein biology, high-throughput functional screening (1,000+ candidates/week with a one-week design-to-screen turnaround), and AI-driven molecular design over curated disease datasets. This platform underpins the company's V-Gate targeting approach, which moves beyond conventional AND-GATE/OR-GATE bispecific logic to enable continuous, fine-tuned target control. Valink is advancing four oncology programs (VLN1–VLN4) through discovery and lead optimisation.

Valink operates a capital-efficient, partnership-oriented business model: it is venture-backed (cumulative ~$19.9M raised across Y Combinator, a 2023 seed led by RV Invest, and a 2025 Pre-A led by redalpine), employs 21 people across a US headquarters in Cambridge, Massachusetts and an R&D subsidiary in London, and generates no commercial product revenue today. Its intended monetization paths are licensing deals, co-development partnerships (exemplified by the December 2025 'Biology to Bispecific' alliance with Nona Biosciences), and eventual out-licensing or commercialization of preclinical assets to larger pharmaceutical companies.

Name

Valink Therapeutics

Legal name

Valink Therapeutics Inc.

Website

https://valinktx.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

11–50 employees

Short description

Valink Therapeutics is a preclinical biopharmaceutical company developing bispecific antibody-drug conjugates for solid tumors using its proprietary LiliumX discovery platform and V-Gate targeting approach, targeting pharmaceutical partners for future co-development and licensing.

Ownership category

akta.pro rank

Product category

Bispecific Antibody-Drug Conjugates (Oncology Therapeutics)

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Antibody-Drug Conjugates (ADCs) & Antibody Conjugates (HLAAAAAE)

akta.pro secondary industries

Bispecific & Multispecific Antibodies (HLAAAAAF), Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI), Oncology Specialty Pharmaceuticals (HLAIACAA)

Keywords

• Bispecific antibody-drug conjugates
• Oncology therapeutics
• Drug discovery platform
• Cancer biologics
• Preclinical ADC development

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Pipeline Development and Licensing: Valink Therapeutics is developing a pipeline of bispecific antibody-drug conjugates for oncology applications. The company is in the preclinical development stage with two oncology programs. Revenue generation will likely come from licensing deals, co-development partnerships, or eventual commercialization of therapeutic candidates.
2. Platform Technology Partnerships: The company leverages its LiliumX discovery platform to forge strategic alliances with other biotech and pharma companies for collaborative drug discovery and development, potentially generating partnership revenue and milestone payments.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Core offering

Valink Therapeutics develops bispecific antibody-drug conjugate (bsADC) therapeutics for solid tumor oncology using its proprietary LiliumX™ discovery platform. The company is advancing a preclinical pipeline of oncology programs (VLN1, VLN2, VLN3, VLN4) targeting colorectal cancer, NSCLC, and pan-cancer indications, with the V-Gate™ approach enabling fine-tuned, continuous-level target control beyond conventional binary gating. Commercial monetization is expected through licensing, co-development partnerships, and milestone/royalty arrangements with larger pharmaceutical companies.

Product overview

Valink Therapeutics is a biopharmaceutical company developing a portfolio of bispecific antibody-drug conjugates (bsADCs) and complementary modalities for oncology. The core of its offering is the LiliumX™ discovery platform, a proprietary high-throughput screening engine combining synthetic protein biology, automation, and AI. This platform powers the V-Gate™ targeting approach, which goes beyond conventional binary gating (AND-GATE, OR-GATE) to enable fine-tuned, continuous-level target control in bispecific ADCs. The company is advancing multiple oncology programs (VLN1, VLN2, VLN3, VLN4) through discovery and preclinical stages, initially focused on colorectal cancer, NSCLC, and other solid tumors. Beyond bsADCs, Valink has developed proprietary protein technologies for dual-payload conjugation, trispecific ADCs, and multivalent antibody platforms. A December 2025 strategic alliance with Nona Biosciences (branded 'Biology to Bispecific') further extends the LiliumX platform by combining it with Nona's Harbour Mice® antibody libraries for expanded bsADC candidate generation.

Differentiator

Problem solved

Functional benefit

Products and services

• LiliumX™ Discovery Platform Proprietary drug discovery engine combining synthetic protein biology, high-throughput functional screening, and AI to rapidly generate and screen bispecific antibody-drug conjugate candidates, with a 1-week design-to-screening turnaround and 1,000+ candidates/week throughput. Used internally by Valink and offered to partners through co-development alliances.
• V-Gate™ Bispecific ADC Targeting Approach Next-generation bispecific ADC targeting logic that enables continuous (non-binary) target engagement, allowing therapeutic binding to cancer cells to be tuned to the continuous levels of each target rather than mere presence/absence. Used within Valink's pipeline and as a differentiated IP-backed targeting concept in licensing discussions.
• Oncology Pipeline — VLN1, VLN2, VLN3, VLN4 Preclinical portfolio of bispecific antibody-drug conjugate programs targeting solid tumors, including an unannounced program, VLN1 (CRC, pan-cancer), VLN2 (CRC, lead optimisation/preclinical), VLN3 (NSCLC, solid tumors), and VLN4. Available for licensing, co-development, or partnership with pharmaceutical companies.
• Biology to Bispecific (B2B)™ Strategic Alliance with Nona Biosciences Strategic alliance that combines Valink's LiliumX discovery platform with Nona Biosciences' Harbour Mice® fully human antibody technology (including heavy chain-only antibodies) to generate and screen thousands of novel bsADC candidates for solid tumors, supporting future co-development and licensing transactions.

Quantifiable outcome

• 1-week turnaround time from design to high-throughput screening experiments (1,000+/week)
• +1 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature5 records

Partnerships

Three partnerships are on record, tiered core.

• Nona BiosciencescoreTechnology or Integration · 17 December 2025Strategic biologics discovery alliance branded 'Biology to Bispecific' (B2B) combining Valink's LiliumX discovery platform with Nona's Harbour Mice antibody technology. The collaboration will generate and screen thousands of novel drug candidates initially focused on bispecific ADCs for solid tumors. The partnership aims to expand Valink's therapeutic pipeline and contribute to future co-development and licensing opportunities.
• Oxford University InnovationcoreTechnology or Integration · 2 November 2023Technology transfer partner from which LiliumX was spun out. Licenses world-class protein conjugation technologies including the SpyTag/SpyCatcher system. Valink is the first company in 24 years formed solely from Oxford's Department of Biochemistry.
• University of OxfordcoreStrategic or Co-development Partner · 18 May 2021Company originated from research conducted at the Department of Biochemistry at the University of Oxford. Founders Arne Scheu and Irsyad Khairil developed 'LEGO' protein technologies during their studies at Oxford.

Scale indicators5 records

Recent moves10 records

Expansion highlights5 records

Direct peers

• Maverick Therapeutics: Bispecific T cell engager biotech (acquired by Takeda). Valink's bispecific ADC work shares the same modular, condition-activated bispecific design philosophy targeting improved therapeutic index.
• Zymeworks: Clinical-stage biotech developing multifunctional therapeutics including bispecific antibodies and ADCs (e.g., zanidatamab, zanidatamab-crowdr). Direct competitor in bispecific antibody engineering with established platform and partnerships.
• Innate Pharma: Clinical-stage biotech using monoclonal antibodies, multi-specific NK cell engagers, and ADCs for cancer immunotherapy. SAB member Sonia Quaratino is Innate's CMO. Comparable in antibody and bispecific ADC development for oncology.
• Mersana Therapeutics: Clinical-stage ADC company developing ADCs for cancer using proprietary payload and linker platforms (e.g., Dolasynthen, Immunosynthen). Direct competitor in ADC development for oncology with SAB overlap (Marc Damelin was previously VP Biology at Mersana).
• Diagonal Therapeutics: Biotech developing agonist antibodies and multispecific biologics, led by Alexey Lugovskoy (also a Valink board member/SAB). Overlap in bispecific and multispecific antibody design for serious diseases, including oncology.
• Iksuda Therapeutics: Clinical-stage biotech developing ADCs and bispecific ADCs for solid tumors. Direct competitor in the bsADC space with overlapping science (Robert Lutz serves as CSO at Iksuda and is also on Valink's SAB), creating both competitive and informational overlap.

Emerging players

• Dragonfly Therapeutics: Developer of multispecific antibodies and cytokine-based therapeutics for cancer and autoimmune disease. Comparable multispecific platform approach; Alexey Lugovskoy was previously COO at Dragonfly.
• Alphina Therapeutics: Early-stage ADC-focused biotech where SAB member Marc Damelin serves as CSO. Comparable in stage and modality focus, and represents a peer for ADC talent and platform competition.
• Janux Therapeutics: Clinical-stage biotech developing T cell engager immunotherapies using bispecific antibody technology (TRACTr platform). Comparable in novel bispecific architecture and oncology focus, though T cell engagers differ mechanistically from bsADCs.
• Generate Biomedicines: AI-driven biologics platform company developing generative protein therapeutics, including ADCs and multispecifics. Comparable AI + protein biology discovery paradigm and early-stage pipeline orientation.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/valinktx

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds4 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Valink Therapeutics